Femasys Appoints John Moorhead to Board of Directors
The Atlanta-based medical company brings on a consumer marketing veteran to help drive its fertility portfolio.
Updated on Oct. 30, 2026 in People
Live Poll
Do you trust companies to appoint leadership that truly represents the needs of their customers?
Femasys Inc. has appointed John Moorhead to its Board of Directors following the company's August 2026 private placement. Moorhead joins as a board designee to help the firm ramp up its direct-to-consumer marketing efforts for fertility solutions.
Why it matters
The company intends to leverage Moorhead’s extensive consumer marketing background to build demand directly among women and OB/GYNs for its fertility offerings. This shift highlights a strategic focus on expanding market reach for its commercialized products.
John Moorhead brings 12 years of experience from his tenure at Unilever’s Seventh Generation to the board. His appointment follows the company’s private placement closing in August 2026.
The players
John Moorhead
He is a marketing executive who recently served as the Head of Marketing for North America at SBM Life Science.
Femasys Inc.
This Atlanta-based medical technology company focuses on developing and commercializing a diverse portfolio of women's health products.
Dr. Kenneth Eichenbaum
He is a medical professional who concluded his tenure as a board designee for the company in October 2026.
The details
Moorhead’s appointment coincides with Femasys’s efforts to commercialize its FemaSeed portfolio and advance its FemBloc product toward U.S. FDA approval. He replaces Dr. Kenneth Eichenbaum, who served as the board designee associated with the November 2025 private placement.
Timeline
November 2025: Dr. Kenneth Eichenbaum began his tenure as a board designee.
2025: FemBloc secured regulatory approvals in Europe, the UK, and New Zealand.
August 2026: Femasys closed a private placement of its stock.
October 30, 2026: John Moorhead was officially appointed to the Board of Directors.
Market Landscape
Femasys is positioning itself to compete in the fertility market as it navigates the rigors of the U.S. FDA 510(k) approval process. By adding consumer-focused leadership, the company aims to differentiate its commercial strategy from competitors relying solely on clinical data.
As Femasys scales its fertility solutions, patients and providers may see increased direct outreach and education regarding available treatment options. These efforts could simplify the decision-making process for individuals seeking specialized fertility care.
The takeaway
Companies in the fertility space are increasingly blending medical innovation with consumer-facing marketing strategies to drive adoption. This transition underscores the growing importance of brand-to-patient communication in the specialized healthcare sector.
Further reading
For more on industry leadership transitions, visit the People section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust companies to appoint leadership that truly represents the needs of their customers?
